Nonsedating alpha-2 agonist 1- (2, 3-dimethyl-phenyl) -ethyl-1, 3-dihydro-imizadole-2-thione

Details for Australian Patent Application No. 2004279332 (hide)

Owner Allergan, Inc.

Inventors Heidelbaugh, Todd M.; Donello, John E.; Chow, Ken; Gil, Daniel W.

Agent Davies Collison Cave

Pub. Number AU-B-2004279332

PCT Pub. Number WO2005/034946

Priority 10/891.953 15.07.04 US; 60/502,562 12.09.03 US

Filing date 20 August 2004

Wipo publication date 21 April 2005

Acceptance publication date 7 October 2010

International Classifications

C07D 233/84 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

A61K 31/4164 (2006.01) - 1,3-Diazoles

A61P 1/00 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/034946 Priority application(s): WO2005/034946

7 October 2010 Application Accepted

  Published as AU-B-2004279332

3 February 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004279333-Methods for identifying improved, nonsedating alpha-2 agonists

2004279331-Inhibitors of cathepsin S